Clinical trial
Enzastaurin Versus Lomustine in Glioblastoma
NCT00295815 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00295815 |
|---|---|
| Title | Enzastaurin Versus Lomustine in Glioblastoma |
| Official title | Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug |
| Interventions | enzastaurin, lomustine |
| Enrollment | 397 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | May 1, 2014 |
| First posted | Feb 24, 2006 |
| Last update posted | Sep 12, 2019 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, India, Italy, Mexico, Netherlands, Poland, Spain and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: